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Research
Recurrent epimutations activate gene body promoters
in primary glioblastoma
Raman P. Nagarajan,1,6 Bo Zhang,2,6 Robert J.A. Bell,1 Brett E. Johnson,1
Adam B. Olshen,1 Vasavi Sundaram,2 Daofeng Li,2 Ashley E. Graham,3 Aaron Diaz,4
Shaun D. Fouse,1 Ivan Smirnov,1 Jun Song,4 Pamela L. Paris,5 Ting Wang,2,7
and Joseph F. Costello1,7
1Brain Tumor Research Center, Department of Neurosurgery, Helen Diller Family Comprehensive Cancer Center, University of California
San Francisco, California 94143, USA; 2Department of Genetics, Center for Genome Sciences and Systems Biology,Washington University
School ofMedicine, St. Louis,Missouri 63108, USA; 3Department ofMicrobiology and Immunology, University of California San Francisco,
California 94143, USA; 4Institute for Human Genetics, University of California San Francisco, California 94143, USA; 5Department
of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California 94143, USA
Aberrant DNA hypomethylation may play an important role in the growth rate of glioblastoma (GBM), but the func-
tional impact on transcription remains poorly understood. We assayed the GBM methylome with MeDIP-seq and MRE-
seq, adjusting for copy number differences, in a small set of non-glioma CpG island methylator phenotype (non-G-CIMP)
primary tumors. Recurrent hypomethylated loci were enriched within a region of chromosome 5p15 that is specified as
a cancer amplicon and also encompasses TERT, encoding telomerase reverse transcriptase, which plays a critical role in
tumorigenesis. Overall, 76 gene body promoters were recurrently hypomethylated, including TERT and the oncogenes
GLI3 and TP73. Recurring hypomethylation also affected previously unannotated alternative promoters, and luciferase
reporter assays for three of four of these promoters confirmed strong promoter activity in GBM cells. Histone H3 lysine 4
trimethylation (H3K4me3) ChIP-seq on tissue from the GBMs uncovered peaks that coincide precisely with tumor-specific
decrease of DNA methylation at 200 loci, 133 of which are in gene bodies. Detailed investigation of TP73 and TERT gene
body hypomethylation demonstrated increased expression of corresponding alternate transcripts, which in TP73 encodes
a truncated p73 protein with oncogenic function and in TERT encodes a putative reverse transcriptase-null protein. Our
findings suggest that recurring gene body promoter hypomethylation events, along with histone H3K4 trimethylation,
alter the transcriptional landscape of GBM through the activation of a limited number of normally silenced promoters
within gene bodies, in at least one case leading to expression of an oncogenic protein.
[Supplemental material is available for this article.]
A hallmark of many cancers is the decrease in 5-methylcytosine in
genomic DNA relative to non-neoplastic cells or tissue, termed
global hypomethylation (Feinberg and Vogelstein 1983; Gama-
Sosa et al. 1983; Wild and Flanagan 2010). Although the degree of
global hypomethylation can be severe, it is not uniformly distrib-
uted across the cancer genome. In colorectal cancer, for example,
large hypomethylated domains coincide with late replication, at-
tachment to the nuclear lamina, and partially methylated domains
(PMDs) in somatic cells (Berman et al. 2011). In many cancers,
demethylation of tandem and interspersed repeats contributes to
global hypomethylation, consistent with repeats containing more
than half of the 28,217,448 CpGs in the human genome (Rollins
et al. 2006). Certain subfamilies of transposons harbor sequences
with enhancer activity that is regulated by epigenetic mechanisms
in a cell-type specific fashion (Xie et al. 2013). However, normally
methylated single copy sequences including those within gene
bodies are also hypomethylated in cancer. In glioblastoma (GBM),
global hypomethylation is found in ;80% of primary tumors
(Cadieux et al. 2006). The level of hypomethylation varies between
individual tumors, ranging from levels seen in normal brain to
;50% of normal, reflecting demethylation of ;10 million CpG
sites per tumor cell on average. Themost severely hypomethylated
GBMs with transcriptional activation of the putative oncogene
MAGEA1 are also the most proliferative, suggesting increased tu-
mor aggressiveness (Cadieux et al. 2006). Furthermore, LINE-1
hypomethylation, potentially reflecting global hypomethylation,
is more pronounced in GBM compared with more indolent lower-
grade glioma (Zheng et al. 2011).
DNA demethylation of specific regulatory elements in cancer
genomes can contribute to the up-regulated expression of the as-
sociated gene. A prototypical example is the 59 promoters of can-
cer-germline (CG) antigen genes (also known as cancer-testis an-
tigen genes) that are methylated and repressed in somatic cells but
demethylated in the germline and some cancers, thereby allowing
CG gene transcription (De Smet et al. 1996). CG promoter hypo-
methylation and gene activation are accompanied by a gain in
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H3K4me3 and histone acetylation (James et al. 2006; Rao et al.
2011). In GBM, severely hypomethylated and hyperproliferative
tumors are associated with demethylation and transcriptional ac-
tivation of the CG gene MAGEA1, a putative oncogene (Cadieux
et al. 2006; Monte et al. 2006). The CG genes SOHLH2, SSX2,
SSX4B, SSX8, SSX9, and PAGE5 are also recurrently hypometh-
ylated in GBM (Wu et al. 2010). Promoter hypomethylation is
associated with transcriptional activation at other single-copy
genes, for example IGF2/H19 (associated with loss of imprinting)
(Cui et al. 2002; Ito et al. 2008), CA9 (Cho et al. 2001), and SRPX2
(Oster et al. 2013). As;98% of 59 promoter CpG islands (CGIs) are
unmethylated in brain (Maunakea et al. 2010), they are more fre-
quently targets of aberrant hypermethylation in cancer (Costello
et al. 2000; Zardo et al. 2002). Thus, potential targets of promoter
hypomethylation in cancer may include CGI promoters in gene
bodies and non-CGI promoters that are methylated, or differen-
tially methylated, in somatic cells (Weber et al. 2007; Meissner
et al. 2008; Maunakea et al. 2010).
Hypomethylation also has the potential to activate cryptic
promoters that are rarely active in normal somatic cells. In-
terspersed transposable elements and endogenous viruses contain
promoters and other functional elements that may have been co-
opted into tissue-specific regulatory networks in normal cells
(Wang et al. 2007; Lynch et al. 2011; Xie et al. 2013). These se-
quences are a potentially vast reservoir of normally silenced,
mostly unannotated promoters that might only become active in
the aberrant epigenetic environment in cancer cells. For example,
hypomethylation of a LINE-1 promoter is associated with activa-
tion of an alternate transcript of the MET oncogene in bladder
tumors and adjacent normal tissue (Wolff et al. 2010). In non-
Hodgkins lymphoma, hypomethylation of an endogenous retro-
virus (ERV) in the THE1B promoter activates transcription of the
adjacent CSF1R proto-oncogene (Lamprecht et al. 2010). The ex-
tent of hypomethylation-associated transcription of endogenous
viral and transposon sequences in GBM is unknown.
Recent genome-wide studies of cancer methylomes have
provided new insights into the distribution and potential molec-
ular consequences of hypomethylation. However, the contribu-
tion of hypomethylation to transcriptional up-regulation, and
which genes are affected, remains unclear. Hypomethylated do-
mains found using 53 coverage shotgun bisulfite sequencing in
colon cancer are associated with extreme expression variability of
the genes within (Hansen et al. 2011). In contrast, in a breast
cancer cell line, hypomethylated blocks were associated with
gene silencing and repressive chromatin (Hon et al. 2012). In
another colon cancer study, focal hypomethylation at enhancers
located 59 of TACSTD2 or within B3GNTL1 was associated with
increased expression of these genes (Berman et al. 2011). These
studies, however, did not distinguish primary transcripts from
overlapping alternative transcripts and did not address alternative
promoter usage.
Identification of recurrent hypomethylation that overlaps
directly with specific regulatory elements, and evaluating changes
in the associated transcripts, is one strategy to further distinguish
functional hypomethylation events in cancer from the potentially
large number of unproductive passenger epimutations. Here we
investigated recurrent, focal hypomethylation in GBM, in anno-
tated and previously unannotated promoters. We mapped full
DNA methylomes for five GBMs, encompassing the three most
common expression subtypes (proneural, classical, and mesenchy-
mal) and including tumors with canonical genetic alterations (e.g.,
EGFR amplification in GBM 2, CDKN2A/B homozygous deletion
in GBMs 2–5, PDGFRA amplification in GBM 5). Our data point to
a role for recurrent gene body hypomethylation in activating nor-
mally silenced alternate promoters and demonstrate up-regulation
of the associated alternative transcripts, and in one case, a protein
isoform that is oncogenic.
Results
Genome-wide identification of differentially methylated
regions (DMRs) using the M&M algorithm
MethylatedDNA immunoprecipitation and sequencing (MeDIP-seq)
and methyl-sensitive restriction enzyme sequencing (MRE-seq)
(Harris et al. 2010; Maunakea et al. 2010) were used to map DNA
methylomes for five newly diagnosed GBMs (Supplemental Table
S1). Unlike bisulfite that conflates methylcytosine and hydroxy-
methylcytosine, MeDIP provides a definitive measurement of
5-methylcytosine only (Jin et al. 2010). Here we identify regions of
hyper- and hypomethylation genome-wide with M&M, a method
that takes into account local CpG density to normalize, scale, and
integrate MeDIP- and MRE-seq data into a single relative mea-
surement that can be compared between samples (Zhang et al.
2013). In contrast to Infinium arrays and reduced representation
bisulfite sequencing (RRBS) which assay 2%–10% of themethylome,
M&M analysis of MeDIP-seq and MRE-seq calls methylation differ-
ences in 500-bp windows across ;80%–90% of the 28 million CpG
sites. Because copy number can confound sequencing-based meth-
ylation methods relying on variation in read density (Laird 2010;
Robinson et al. 2010), we performed array-CGH on each GBM and
normalized MeDIP- and MRE-seq signals across the genome by
estimated copy number (Methods; Supplemental Fig. S1A–R).We
also analyzed global mRNA expression by microarray to identify
potential functional effects of recurrent epigenetic alterations,
and used the Illumina Infinium HumanMethylation27 array for
large-scale validation of ourM&M results. Based on copy number
and expression profiles, the three most common GBM expres-
sion subtypes (Verhaak et al. 2010) are represented in our small
sample set (proneural, classical, and mesenchymal) (Supple-
mental Table 1). Methylation changes in the rare IDH1 mutant,
G-CIMP positive GBM class, which represent 5%–10% of all
GBM, have been described elsewhere using Infinium arrays
(Noushmehr et al. 2010).
To discover differentially methylated regions (DMRs), we
compared each GBM to normal brain samples from two indi-
viduals separately and identified 500-bp windows, excluding sex
chromosomes, which were significantly different in both GBM-
normal comparisons. The two normal brains (frontal cortex from
two adult males) were very similar though not identical (Supple-
mental Fig. S2A; Maunakea et al. 2010). Using M&M at a stringent
threshold of Q < 1013, we identified between 343–2288 hyper-
methylated and 4–2124 hypomethylated DMRs across the five
GBMs (Fig. 1A).We also used a less stringent cutoff ofQ < 105 and
found additional DMRs with similar relative frequencies among
tumors (Supplemental Fig. S2B). Proneural GBM 5 presented an
unusual profile of frequent hypermethylation, within range of
the other GBMs, but sparse hypomethylation; however, none of
the GBMs were of the glioma-CpG island methylator phenotype
(G-CIMP), based on Infinium array data at diagnostic loci
(Noushmehr et al. 2010). Hierarchical clustering of all probes in-
dicated that the pattern of GBM 5 methylation was most closely
related to normal brain of the five GBMs (data not shown). His-
topathological analysis showed;95% tumor cell purity forGBM5,
762 Genome Research
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and the magnitude of hypermethylation was similar compared
with the other GBMs, suggesting that the infrequent hypo-
methylation in this tumor is likely not due to significant admix-
tures of normal cells.
For large-scale validation of the M&M candidate DMRs, we
plotted delta beta values (GBM-normal brain) for each Infinium
HumanMethylation27 CpG site within a DMR (Fig. 1B; Supple-
mental Fig. S3). For eachGBM, a very consistent overallmethylation
change was observed in the Infinium data for both hyper- and
hypomethylated DMRs, even though the
arrays measure individual CpG sites while
M&M estimates methylation in 500-bp
windows, and despite the differences in
detection of hydroxymethylation by
these two methods. We further validated
several individual loci by the ‘‘gold
standard’’ of bisulfite PCR, cloning and
Sanger sequencing. We chose a hypo-
methylated locus within the TRPM5
gene body and a hypermethylated locus
at the BCL2L11 promoter and in both
cases confirmed the M&M DMR calls
(Fig. 1C,D; Supplemental Fig. S4A,B). We
also tested the accuracy of M&M in
detecting DMRs at uniquely mapping
sequences derived from transposons. At
two loci examined (one MER52A ERV
and one LTR1B), hypomethylated DMRs
were confirmed by bisulfite sequencing
(Supplemental Fig. S5A–D).
To highlight functionally relevant
methylation alterations, we identified
DMRs shared between two or more GBMs
(Table 1). Recurrent hypermethylated
and hypomethylated DMRs showed strik-
ing differences in genomic distribution.
Recurring hypermethylation showed
strong enrichment for CGIs (40–503) and
moderate enrichment for promoters, 59-
untranslated regions (UTRs), and exons
(Fig. 2). In contrast, recurring hypometh-
ylated DMRs were relatively infrequent
in CGIs and promoters compared with
hypermethylation. To some degree, these
patterns reflect the genomic distribution
ofmethylation in brain and other normal
somatic tissues, i.e., most of the genome
is highly methylated except for discrete,
almost completely unmethylated regions
corresponding to CGIs. In colon cancer,
partiallyhypomethylateddomains (PMDs),
encompassing up to half the genome,
have been reported to coincide with nu-
clear lamina attachment regions (LADs)
(Berman et al. 2011; Hansen et al. 2011).
In our GBM data, 29.5% of recurring
hypomethylated DMRs localize within
LADs, compared with a genomic back-
ground of 36.9%. We analyzed MeDIP
reads per kilobase per million mapped
reads (RPKM) in 20- and 50-kb windows
genome-wide but did not detect large-
scale differences between GBMs and normal brain (not shown). Al-
though some broad regions of low-magnitude hypomethylation
might be below the threshold of detection, the focally hypo-
methylated DMRs we identified are primarily not associated with
LADs.We also examinedmethylation alterations at CGIs byMeDIP-
seq RPKM, independent from the M&M analysis. By this approach,
147/157 (94%) of recurring hypomethylated CGIs in GBM were
stronglymethylated in normal brain (Table 2). Approximately 68%
of these hypomethylated CGIs were located within gene bodies.
Figure 1. Discovery and validation of DMRs in GBM. (A) Number of hypermethylated and hypo-
methylated DMRs at Q < 1013 in five primary GBMs. The expression subtype (Verhaak et al. 2010) of
each tumor is shown below. (n.d.) Not determined. (CL) Classical. (PN) Proneural. (MES) Mesenchymal.
(B) Delta beta values (GBM-normal brain) from Infinium HumanMethylation27 arrays, plotted for in-
dividual CpGs within hyper- and hypomethylated DMRs (Q < 1013) for each of five GBMs. For GBM 5,
there were no InfiniumCpGswithin hypomethylatedDMRs. (n.d.) No data. (C,D) Validation of gene body
hypomethylation in TRPM5 by bisulfite cloning and sequencing. In C, the location of hypomethylation is
shown within the TRPM5 gene body. Normalized MeDIP-seq coverage is graphed in brown for normal
brain andblue forGBM. ForMRE-seq, normalized read counts at single CpGs are in green. For GBM tracks,
MeDIP-seq and MRE-seq values are normalized by copy number and sequencing depth. In D, bisulfite
PCR, cloning, and sequencing results are shown for 20 CpGs in the region ‘‘bisulfite PCR amplicon’’ in C.
Each row is a clone and each column is a CpG site. Asterisks indicate CpGs with MRE sites.
Recurrent epimutations in gene bodies
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Together, these data show that normally methylated gene bodies
and intergenic regions, which are sites of alternate promoters,
enhancers, and other regulatory elements, are commonly affected
by hypomethylation in GBM.
Functional analysis of recurring hypermethylated DMRs us-
ing GREAT (McLean et al. 2010) uncovered highly significant en-
richments for genes bound by Polycomb complex proteins and
marked by H3K27me3 in embryonic stem cells (Supplemental
Table S2; Ohm et al. 2007; Schlesinger et al. 2007; Widschwendter
et al. 2007). This corroborates similar results in GBM obtained by
other methods (Martinez et al. 2009; Wu et al. 2010). Significant
enrichment was also observed for gene sets affected by CGI pro-
moter hypermethylation in other cancer types.
Because of the strong focus on hypermethylation in cancer,
less is known about the genes and pathways affected by hypo-
methylation.GREATenrichments for hypomethylatedDMRs from
individual GBMs were diverse, with relatively few commonalities
between these tumors with shared GBM histology but differing
molecular subtype. A highly significant hypomethylation enrich-
ment, common to four of five individualGBMs and also significant
in recurring hypomethylated DMRs, was for an;3.4-Mb region of
chromosome 5p15 that contains 26 genes and is recurrently am-
plified in breast cancer (Supplemental Table S3; Nikolsky et al.
2008). This region is not amplified in our five GBMs, but encom-
passes a large number of hypomethylated DMRs including a re-
current hypomethylated DMR in the gene body of TERT, encoding
telomerase reverse transcriptase which
plays a critical role in telomere length and
tumorigenesis.
Because promoter hypomethylation
is hypothesized to be one mechanism
leading to oncogene overexpression
(Hoffman 1984), we carefully examined
the promoter methylation status of GBM
oncogenes. We did not detect hypo-
methylation at the 59 promoters of 16
prototypical oncogenes that are recur-
rently activated by genetic mechanisms in
GBM (McLendon et al. 2008), though
many of these have 59 CGIs that are
unmethylated in normal brain (Supple-
mental Fig. S6A). These findings are con-
sistent with the genomic distribution of
hypomethylated DMRs (Fig. 2), which
suggest that CGIs and 59 promoters are
rarely targets of hypomethylation. We
confirmed the absence of oncogene pro-
moter hypomethylation in a large GBM
data set from The Cancer Genome Atlas
(TCGA). Analysis of Infinium Human-
Methylation27 methylation data for 292
TCGA GBMs showed that oncogene CGI
promoters are almost always fully unmethylated in both normal
brain and GBM, but at a few regions are in fact hypermethylated in
a subset of GBMs, e.g., at a portion of the CCND2 promoter marked
by Polycomb-associated H3K27me3 in embryonic stem cells (Sup-
plemental Fig. S6B,C). It is unlikely that this hypermethylation in-
hibits transcription, as it is confined to the part of the CGI that is
distal from the transcription start site (TSS). For non-CGI promoters,
the TCGA data show high or low methylation, depending on the
CpG site assayed, but at similar levels in GBM and normal brain.
As aberrant hypomethylated DMRs were rare at 59 promoters,
we hypothesized that gene body and intergenic regulatory ele-
ments, including alternate promoters, could be targets of hypo-
methylation. We plotted average ENCODE DNase I hypersensi-
tivity (DHS) across 10.5-kb windows centered on the complete set
of recurring hypomethylated DMRs (Q < 1013) (Supplemental
Fig. S7). Hypomethylated DMRs were enriched for DHS, centered
near the middle of the DMRs and rapidly dropping to background
in flanking regions. The DHS enrichment is likely driven by
colocalization of a subset of hypomethylated DMRs with regula-
tory elements, as well as the innate regulatory capacity of many
CpG-containing sequences.
Tumor-specific hypomethylation of alternative promoters
in gene bodies
The genomic distribution of hypomethylation and the enrichment
of hypomethylated DMRs for epigenetically defined regulatory re-
gions suggested that activation of alternative promoters in gene
bodies could be one consequence of GBM hypomethylation. We
utilized annotated gene body promoters from the UCSC Known
Genes (Hsu et al. 2006), which encompasses a greater number of
transcripts compared with RefSeq. Gene body promoters were de-
fined as 2 to +0.5 kb relative to all UCSC TSS located 39 of the 59-
most TSS for the samegene. Seventy-six geneswere sites of recurring
gene body promoter hypomethylation, determined by the presence
of at least one hypomethylated DMR (Q < 105) in two or more
Table 1. Recurring DMRs present in at least two GBMs
Q < 10L13 Q < 10L5
Recurring hypermethylated DMRs 1144 10,178
Recurring hypomethylated DMRS 558 4498
The numbers of recurring DMRs, defined as those that are present in at
least two GBMs, are shown at Q < 1013 and Q < 105.
Figure 2. Enrichment for genomic features among recurring hyper- and hypomethylated DMRs at
Q < 1013 and Q < 105. Enrichment was calculated using the background distribution of CpG-
containing 500-bp windows on autosomes that were also used for M&M analysis. Statistically significant
enrichment (or depletion) was calculated using a binomial test, and those significant at P < 0.001 are
indicatedwith asterisks. The definitions of genomic features are the following: intergenic: regions between
39 transcription end site (TES) of a gene to the 59-most TSS of next gene; gene body: 59-most TSS of a gene
to 39-most TES of the same gene; CGIs: from UCSC annotation; promoter: 2.5 to +0.5 kb from the 59-
most TSS. 59 UTRs, exons, introns, and 39 UTRswere defined from the RefSeq database. Note that some of
these genomic features are not mutually exclusive.
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GBMs. Nearly all (71/76; 93%) were not associated with any sig-
nificant methylation change at the corresponding 59 promoter of
the same gene (neither hypo- nor hypermethylation). Three genes
(TERT, TP73, DIO3OS) had concurrent 59 hypermethylation in at
least two GBMs with gene body promoter hypomethylation,
though the 59 hypermethylation was focal and did not encompass
the core promoter. The other two genes, LSP1 and DMKN, had
hypomethylated promoters in the gene body and 59 region.
Tumor-specific hypomethylation at candidate alternative
promoters in gene bodies
In addition to the above recurrently hypomethylated gene body
promoters, cryptic promoters not previously associatedwith the 59
ends of RefSeq or UCSC Known Genes transcripts might be novel
targets of GBM hypomethylation. We used chromatin states de-
fined by the ChromHMM algorithm, which defines regulatory el-
ements based on combinatorial histone modifications (Ernst et al.
2011), to identify putative promoters. We annotated each 500-bp
genomic window by the presence of the following chromatin
states in at least one ENCODE cell type: (1) active, weak, or poised
promoter (Ernst et al. 2011, states 1–3), (2) active or weak/poised
enhancer (states 4–7), or (3) insulator (state 8) (Methods). We
found that 364/4498 (8.1%) of recurring hypomethylated DMRs
(Q < 105) occurred at ChromHMM-defined promoters (Fig. 3A).
Many hypomethylated DMRs are potential enhancers or in-
sulators, and some overlap with apparently multifunctional loci,
with different regulatory functions depending on cell type.
We used the ChromHMM annotations to detect hypo-
methylated novel promoters identified solely by promoter chro-
matin state that were >2 kb intragenic or intergenic from the 59 or
39 boundaries of RefSeq and UCSCGenes transcripts. The presence
of ENCODE transcription factor binding sites, DNase I hypersen-
sitivity, and 59 ends of GenBank mRNAs and ESTs at four such loci
strongly suggested promoter function, which we tested experi-
mentally. Three of these loci were located within gene bodies and
a fourth was intergenic (Supplemental Fig. S8A,B).
We cloned each of the four candidates into the pGL3-basic
reporter vector and quantified promoter activity by luciferase assay
in HEK293 cells and twoGBMcell lines, LN229 andU87. The three
putative gene body promoters exhibited significant promoter ac-
tivity in all cell lines (Fig. 3B–D). The TNXB gene body promoter
showed particularly strong activity in U87 and LN229 cells, with
the smaller of two cloned fragments harboring activity evenhigher
than the SV40positive control inU87GBMcells.TNXB encodes an
extracellular matrix glycoprotein of the tenascin family that is
expressed in GBM, possibly with a role in promoting neo-
vascularization (Hasegawa et al. 1997).
The SIGLEC11 gene body promoter is located within a HERV3
ERV repeat (Fig. 3E). Human TSS profiling using cap analysis of
gene expression (CAGE) tag sequencing had previously identified
this region as a site of transposon-associated transcriptional initi-
ation (Faulkner et al. 2009). TheCAGE reads supporting a TSS came
from the MCF7 breast cancer cell line (not shown). ChIP-seq for
H3K4me3 identified a peak in GBM 5 and slight enrichment in
GBMs 1 and 2 at the region overlapping the confirmed promoter.
Three human ESTs, including one from an ovarian tumor, sug-
gested transcription initiation within SIGLEC11 intron 7 (Fig. 3E).
Because these do not overlapwith known SIGLEC11 exons, the EST
sequences allowed us to design RT-PCR primers specific for the
putative gene body transcript. We first confirmed with conven-
tional endpoint PCR complete lack of amplification from reverse
transcriptase-negative controls for each of our GBMs and normal
brains, using two independent primer pairs (data not shown). We
then used qRT-PCR to quantify relative expression of the alternate
transcript, again including RT-negative controls for all samples. We
found that GBM1, which was partially hypomethylated at the gene
body promoter, expressed the alternate transcript almost 16-fold
higher than normal brain (Fig. 3F). Interestingly, the other hypo-
methylatedGBMsdidnot showup-regulated expression, suggesting
that additional factors are required for efficient transcription initi-
ation. These data show that novel or cryptic promoters are targets of
GBM hypomethylation and can drive expression of normally si-
lenced gene body transcripts from transposons.
Acquisition of H3K4me3 in primary GBM at a subset
of recurrently hypomethylated DMRs
In addition to examining the relationship between histone
modifications fromENCODE cell lines and hypomethylatedDMRs
in GBM, we sought to directly link DNA hypomethylation with
promoter-associated histone modification profiled in the same
primary GBM tissues. We performed tissue-ChIP-seq for H3K4me3
on GBMs 1, 2, and 5. We used MACS (Zhang et al. 2008) with a 1%
false discovery rate and P-value cutoff of 1 3 1010 to identify re-
gions with localized H3K4me3 enrichment in GBM 1 (68,675
peaks), GBM 2 (57,748 peaks), and GBM 5 (47,719 peaks). We
confirmed the quality of the ChIP-seq data with CHANCE (Sup-
plemental Fig. S9; Diaz et al. 2012). In addition,we found that 51%–
55% of GBM H3K4me3 peaks overlap with the ChromHMM pro-
moter state in at least one of the nine ENCODE cell lines analyzed in
Ernst et al. (2011) (Supplemental Fig. S10).
We identified 200 loci with both H3K4me3 peaks and DNA
hypomethylation (Q < 105) in total over three GBMs (DNA hypo/
K4me3 loci). Of these, 133 were within gene bodies. Most were
specific to a particular tumor, although nine were shared between
two GBMs (Supplemental Fig. S11). GREAT functional analysis
identified significant enrichment for multiple cancer-related gene
sets (Supplemental Table S4).We examinedmRNA expression levels
of genes with gene body DNA hypo/K4me3 loci by Affymetrix
Table 2. GBM CGI hypomethylation
Normal brain high methylation Normal brain low methylation Total
All CpG islands (CGI) (%) 5676 (21%) 21,938 (79%) 27,614
Recurring hypomethylated CGI 147 (94%) 10 (6%) 157
Recurring hypomethylated DMRs (Q < 105) overlapping CGI 247 (86%) 39 (14%) 286
GBM hyper- and hypomethylation at 27,614 CGIs were analyzed by calculating RPKM from MeDIP-seq. First, we categorized each CGI as either
methylated (2nd column) or unmethylated (3rd column) in normal brain. Most CGIs (79%) are unmethylated in normal brain. Within these categories,
we then determined how many CGIs were recurrently hypomethylated in GBM by MeDIP-seq RPKM (second row). In the bottom row, we used the CGI
categorization by RPKM and determined the occurrence of M&M hypomethylated DMRs within each category.
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GeneChip Human Gene 1.0 ST arrays. In each GBM, we observed
both increased and decreased gene expression relative to normal
brain, but overall these genes showed increased expression (Fig.
4A). In GBMs 1 and 5 the increased expression was statistically
significant (P = 2.9 3 106 and P = 0.02, respectively). The partial
association between DNA hypo/K4me3
loci and expression is likely because not
all DNA hypo/K4me3 loci are promoters
driving expression of alternate transcripts
of their ‘‘host’’ genes. Some might drive
antisense expression or splice to distal
downstream exons. In addition, mea-
surements of gene expression by array
might not capture the most relevant
exons for measuring expression of spe-
cific alternate transcripts, which are more
precisely distinguished by manual, tran-
script-specific qRT-PCR or RNA-seq.
Twenty-two of the 76 recurrently
hypomethylated gene body promoters
we identified above also had H3K4me3
peaks in at least one GBM (Supplemental
Fig. S12). The promoter of Delta GLI3,
a transcript variant of GLI3 (glioma-
associated oncogene family zinc finger 3),
was one example and showed recurrent
colocalization of DNA hypomethylation
and H3K4me3 (Fig. 4B). Full-length GLI3
mRNA expression was up-regulated by
expression microarray (data not shown).
All five GBMs had increased copy number
for the entire chromosome 7, which
could partially but not fully account for
the increased expression. For example,
GBM 5 had a 2.7-fold increase in GLI3
expression and only a 1.2-fold copy num-
ber increase relative to diploid. The gene
body promoter had H3K4me3 peaks
in GBMs 1, 2, and 5, and was partially
hypomethylated in all five GBMs, with
hypomethylated DMRs found in GBMs 2
through 5 (Fig. 4B).We confirmed that the
gene body promoter hypomethylation
was recurrent by analysis of TCGA
HumanMethylation450 methylation array
data from 126 GBMs (Supplemental Fig.
S13A,B). Since our microarray data were
not specific for the Delta GLI3 transcript,
we performed isoform-specific qRT-PCR to
quantify Delta GLI3 in the GBMs with
both hypomethylation and H3K4me3 at
the Delta GLI3 promoter. We found in-
creased mRNA expression in GBMs 1 and
5 relative to normal brain (Fig. 4C). GBM5
showed the highest expression and we
observed H3K27ac enrichment at the
Delta GLI3 promoter in GBM 5, consis-
tent with epigenetic activation (RJA Bell, J
Song, JF Costello, unpubl.). This DNA
hypo/K4me3 locus is evolutionarily con-
served (a phastCons conserved element in
primates,mammals, andvertebrates) and is
a site ofDHS, transcription factor binding, andChromHMMpromoter
state in some ENCODE cell lines (not shown). GLI3 encodes one of
a family of three zinc finger domain transcription factors that
signal in the Sonic Hedgehog pathway. The Delta GLI3 mRNA
contains a 1521 a.a. open reading frame for an in-frame GLI3
Figure 3. Recurrent DNA hypomethylation of previously unannotated promoters in GBM. (A)
ChromHMM-defined promoters, enhancers, and insulators from nine ENCODE cell lines overlap with
recurrent GBM hypomethylated DMRs (Q < 105 in at least two of five GBMs). (B–D) Promoter assays for
DNA sequences within hypomethylated DMRs that were not associated with the 59 ends of RefSeq or
UCSC transcripts, but had a promoter state assigned by ChromHMM in at least one ENCODE cell type.
Each bar shows fold induction (6SD) relative to pGL3-Basic empty vector control. pGL3-SV40 promoter is
used as a positive control, shown immediately to the right of the empty vector. These candidate promoters
were tested inHEK293 cells and twoGBMcell lines, U87 and LN229. Asterisks indicate P < 0.05, one-tailed
t-test. (E) Previously unannotated alternative promoter in the body of SIGLEC11 showing GBM hypo-
methylation and overlapping promoter state by ChromHMM. The region cloned for luciferase assay is
shown in blue, and human ESTs suggesting transcription initiation are shown below (black). LTR repeats
from UCSC RepeatMasker track, including the HERV3 element in which the promoter is embedded, are
indicated with gray. The location of a transposon-associated CAGE tag cluster (Faulkner et al. 2009) is
shown by the purple hatch mark. H3K4me3 ChIP-seq signal in GBMs 1, 2, and 5 is shown at the bottom.
(F) qRT-PCR with primers located within human EST BM977347 (see E). Fold expression 6 SD relative to
normal brain is graphed for a representative experiment. (NB) Normal brain.
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alternate protein, lacking the N-terminal region compared with
the 1580 a.a. full-length GLI3, but otherwise identical to the full-
length protein. The function of the delta GLI3 isoform, and
whether it differs from full-length GLI3, is not known.
Tumor-specific gene body hypomethylation is associated
with increased expression
of an oncogenic isoform of TP73
We investigated in depth a hypomethylated gene body CGI pro-
moter in the TP53-related gene TP73. This alternative promoter was
recurrently hypomethylated, with the
strongest hypomethylation overlapping
the alternate TSS in GBM 3 (Fig. 5A). TP73
encodes multiple protein isoforms with
opposing tumor suppressor and onco-
genic functions, depending on alternate
promoter usage and splicing (Rufini
et al. 2011). The transcript produced
from the gene body promoter, DeltaN
TP73, encodes the oncogenic deltaNp73
protein, a dominant negative inhibitor
of p73 and p53 signaling (Ishimoto et al.
2002). We validated gene body pro-
moter hypomethylation by bisulfite
PCR, cloning, and Sanger sequencing
(Fig. 5B). In two normal brains and GBM
1, the gene body promoter was highly
methylated (>90% average methylation
across 12 CpGs). GBM 3 was severely
hypomethylated (34% average methyla-
tion) and nine of the 15 sequenced
clones were completely or nearly com-
pletely unmethylated, consistent with
a transcriptionally active, open chro-
matin state at these alleles in a signifi-
cant fraction of the tumor. Infinium
methylation array data from the same
GBMs were concordant with MeDIP/MRE
data and bisulfite sequencing (Fig. 5C;
data not shown).
TP73 gene body promoter hypo-
methylation was associated with up-
regulation ofDeltaN TP73mRNA.DeltaN
TP73was;13-fold overexpressed in GBM
3 comparedwithnormal brain by isoform-
specific qRT-PCR, and was higher than
GBMswithout hypomethylation (Fig. 5D).
DeltaN TP73 expression was low, similar
to normal brain, in fetal neural stem cells
(FNSC) as well as established GBM cell
lines and in a short-term culture of GBM
5. DeltaN TP73 mRNA was also dramati-
cally increased during tumor progression
in two of two patients with secondary
GBM relative to their patient-matched,
indolent low-grade gliomas resected years
earlier (Q = 4.93 106 andQ = 1.33 106,
RNA-seq data [ Johnson et al. 2013]).
We next determined whether
hypomethylation-associated mRNA up-
regulation resulted in expression of the
deltaNp73 protein. DeltaNp73 has a unique N terminus and lacks
the transactivation domain found in full-length p73, but shares
a C-terminal localization domain with full-length p73, accounting
for its dominant negative function. Western blotting with a del-
taNp73-specific antibody revealed expression in multiple GBMs
including GBM3, but undetectable or very low deltaNp73 in two
normal brains, GBM cell lines, and primary GBM cultures (Fig.
5E). As deltaNp73 was expressed in GBMs without hypo-
methylation-associated DeltaN TP73 expression, gene body
hypomethylation may be one of multiple mechanisms influ-
encing the deltaNp73 protein level in GBM. Another mecha-
Figure 4. A subset of recurrent DNA hypomethylation coincides with H3K4me3 in the same primary
tumor. (A) Gene expression change for genes nearest each DNA hypo/K4me3 locus, which, taking into
account the direction of transcription, can be located upstream (59), within the gene body, or
downstream (39). Hypomethylated DMRs at Q < 105 and H3K4me3 peaks (P < 13 1010) were used
to define DNA hypo/K4me3 loci. The Affymetrix GeneChip Human Gene 1.0 ST expression changes
(GBM-NB) for the nearest RefSeq gene are shown as box plots on a log2 scale. The number of genes
analyzed in each box plot is given along with the labels at the bottom. Statistically significant gene
expression changes were determined using a t-test at P < 0.05 (asterisks above box plots). A total of
19,628 Entrez genes were analyzed on the array. (B) Recurring colocalization of DNA hypo-
methylation and H3K4me3 at the Delta GLI3 transcript promoter. Individual hypomethylated DMRs
are shown under the MRE. (C ) Quantification of Delta GLI3 transcript abundance by isoform-specific
qRT-PCR. Fold expression 6 SD relative to normal brain is graphed for a representative experiment.
(NB) Normal brain.
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nism involves alternate splicing of transcripts initiating from
the 59 promoter, which can also produce a transcript encoding
the deltaNp73 protein (Ishimoto et al. 2002).Our qRT-PCR primers
are specific for gene body promoter transcript, and do not am-
plify the alternately spliced 59 transcripts.
Hypermethylation of the 59 promoter and hypomethylation
of the gene body promoter of TP73 are recurrent but not correlated
Although TP73 gene body hypomethylation was pronounced in
one of our five GBMs, we hypothesized that it might be a recurrent
epimutation detectable in a larger tumor cohort. To address this
question, we analyzed TCGA HumanMethylation27 array data
from 292 GBMs. The TP73 gene body promoter is assayed by the
array at four CpG sites including three in
the hypomethylated region that we pre-
viously validated with bisulfite sequenc-
ing (Fig. 5B,C). In addition, four of nine
59 promoter probes interrogate a region
where we observed recurring hyper-
methylation of ;1 kb of the 3191-bp
59 CGI (Supplemental Fig. S14A). We
plotted methylation levels for these 13
TP73 probes for the entire cohort of 292
TCGA primary GBMs (Fig. 5C; Supple-
mental Fig. 14B). Both gene body hypo-
methylation and 59 hypermethylation
were highly recurrent events with varying
magnitude. However, hypomethylation
and hypermethylation were not corre-
lated (r = 0.12, Pearson correlation), con-
sistent with the nearly complete lack of
methylation change at the 59 endof 71out
of 76 genes with recurring gene body
promoter hypomethylation that were
discovered by M&M analysis. These data
strongly suggest that different mecha-
nisms underlie hypomethylation of alter-
native promoters in gene bodies compared
with DNA methylation changes in 59
promoters.
GBM-specific expression of a TERT
alternate transcript from a
hypomethylated gene body
promoter
TERT encodes telomerase reverse tran-
scriptase and is located within a broad re-
gion of recurring GBM hypomethylation
on chromosome 5p15. Functional en-
richment analysis by GREAT found that
individual and recurring hypomethylated
DMRs significantly enriched for a gene set
corresponding to recurrent 5p15 genomic
amplification in breast cancer (Nikolsky
et al. 2008), and numerous hypometh-
ylated DMRs are found in this region
(Fig. 6A). Up-regulation of TERT mRNA
leads to increased telomerase activity in
most cancers, facilitating telomere main-
tenance, unlimited proliferation capacity,
and immortalization (Meyerson et al. 1997; Shay and Bacchetti
1997). TERTmRNA is expressed, and telomerase activity is detected
in themajority of primaryGBM (Le et al. 1998; Lotsch et al. 2013). A
SNP (rs2736100) in the TERT gene body is associated with suscep-
tibility to glioma in several genome-wide association studies
(GWAS) (Shete et al. 2009; Wrensch et al. 2009; Rajaraman et al.
2012). In addition, highly recurrent TERT promoter mutations,
potentially generating binding sites for ETS/TCF transcription
factors and presumably mediating increased TERT transcription,
have recently been reported in GBM, low grade glioma, hereditary
and sporadic melanoma, and other cancers (Horn et al. 2013;
Huang et al. 2013; Killela et al. 2013).
ThreeGBMshad a hypomethylatedDMR (Q < 105) at aTERT
gene body promoter, and increased MRE-seq was observed at this
Figure 5. TP73 gene body CGI hypomethylation associated with activation of the oncogenic DeltaN
TP73 isoform. (A) Strong focal hypomethylation in GBM 3 detected by MeDIP-seq and MRE-seq. (B)
Bisulfite sequencing for two normal brains (top) and GBMs 1 and 3 (bottom). Asterisks indicate CpGs
with MRE sites. (C ) Infinium HumanMethylation27 array data at the DeltaN TP73 promoter. Percent
methylation for four CpGs, shown schematically at the top, is graphed below. (Gray points) 292 TCGA-
assayed GBMs. (Black squares) GBM 3. (Black triangles) Normal brains. (D) Quantitative RT-PCR for the
oncogenic DeltaN TP73 mRNA isoform. Fold expression 6 SD relative to the average of two normal
brains is graphed for a representative experiment. (NB) Normal brain. (FNSC) Cultured fetal neural stem
cells. (U87) GBM cell line. (GBM5 cult.) Short-term serum-grown culture of GBM5. (E) Western blotting
with anti-deltaNp73 (top) and anti-GAPDH control (bottom).
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region in all five GBMs (Fig. 6B). Two CpGs are present on the
Infinium HumanMethylation450 array within this recurring
hypomethylated DMR, and we plotted methylation levels at
these CpGs for 126 GBMs assayed by the TCGA (Fig. 6C). Forty-
two percent (CpG #1) and 56% (CpG #2) of GBMs had <80%
methylation, whereas normal brain was >90% methylated at both
sites. The UCSC KnownGenes annotates an alternate TERTmRNA,
which we term Delta TERT, initiating within the hypomethylated
gene body CGI, supported by a full-length cDNA from Burkitt’s
lymphoma (Fig. 6B). To determine if
a spliced mRNA is transcribed from this
putative gene body promoter, we per-
formed exon-joining RT-PCR with
primers in the 39 UTR and putative 59
UTR to amplify the entire coding portion
of Delta TERT from GBM cDNA (Sup-
plemental Fig. S15A,B). The exon splic-
ing structure matched the UCSC Genes
alternate transcript, with exons 7 and 8
(numbering based on the full-length
transcript) spliced out. We next designed
isoform-specific qRT-PCR primers to
quantify expression of Delta TERT and
observed elevated expression in GBMs 1,
3, and 5 (Fig. 6D). Its expression was low,
similar to normal brain, in cultured
FNSCs and in the GBM cell line U87. We
also performed 59-rapid amplification of
cDNA ends (59-RACE) on GBM 3, which
showed elevated expression by qRT-PCR
and for which we had abundant high-
quality RNA. We detected gene body
transcription initiating from a single TSS
within theCGI (Fig. 6E). NoRACEproduct
was observed in a negative control re-
action performed on FNSC RNA.
Together, the 59-RACE, exon-joining RT-
PCR, and qRT-PCRdata indicate recurrent
expression of Delta TERT from a hypo-
methylated gene body promoter in GBM.
The alternate transcript includes an open
reading frame encoding a putative short
TERT protein of 329 amino acids, which
shares the C terminus with full-length
TERT but lacks part of the N-terminal re-
verse transcriptase domain (Supplemental
Fig. S15C). One of the three catalytic
aspartic acid residues critical for reverse
transcriptase activity, D712, is absent from
the putative short protein, likely compro-
mising the ability to maintain telomere
ends. Alternatively, as recently described
for full-length TERT, it may have a func-
tion unrelated to telomere maintenance
such as transcriptional regulation (Park
et al. 2009).
Discussion
Recent studies have described the patterns
of DNA hyper- and hypomethylation in
cancer, but in most cases it is not yet clear
which, if any, events are drivers of tumor phenotypes versus which
ones have little or no effect on transcription, andmay be passenger
events. Herewe sought tomore fully understand hypomethylation
in GBM, especially how it relates to regulation of alternate pro-
moters. We have recently highlighted the importance of tissue and
cell-type specific DNA methylation in gene bodies in the regula-
tion of alternative transcripts (Maunakea et al. 2010).We identified
focal hyper- and hypomethylation with M&M, normalizing for
copy number, and validated methylation changes with both
Figure 6. GBM-specific expression of an alternate transcript from a hypomethylated promoter in the
TERT gene body. (A) GBM individual hypomethylated DMRs (Q < 105) within a;3.4-Mb region that is
recurrently amplified in breast cancer and is enriched by GREAT analysis of recurring and individual
hypomethylated DMRs. The location of the breast cancer copy number amplicon is shown in gray at the
bottom. (B) GBM hypomethylation at a TERT gene body promoter, which is located near the glioma risk
SNP rs2736100. GBMs 1, 2, and 4 had hypomethylated DMRs (Q-values are 1014, 1014, 1021). (C )
Infinium HumanMethylation450 array data for two CpGs in the recurrent hypomethylated DMR at the
Delta TERT promoter. (Gray points) 126 TCGA-assayed GBMs. (Black triangles) TCGA normal brain. The
percentage of GBMs at each CpG with methylation <80% (red line) is shown in red text. (D) Delta TERT
mRNA isoform abundance quantified by qRT-PCR. Fold expression 6 SD relative to the average of two
normal brains is graphed. (NB) Normal brain. (FNSC) Cultured fetal neural stem cells. (U87) GBM cell
line. (GBM5 cult.) Short-term serum-grown culture of GBM 5. (E) Detection of the transcription initi-
ation site within the TERT hypomethylated gene body by 59-RACE.
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Infinium array and bisulfite sequencing. Although promoter
hypomethylation did not occur at oncogenes that are commonly
genetically altered in GBM, we found that alternate promoters in
bodies of a small number of genes with potential oncogenic
function are targets of recurrent GBM hypomethylation, and in
some cases show concurrent gain of H3K4me3.
Many genome-wide methylation studies examine promoters
defined by the 59 ends of transcripts annotated in databases such as
RefSeq (Pruitt et al. 2007). However, there is accumulating evidence
for widespread transcription and regulatory elements throughout
amajority of the genome that are not yet well annotated andwhich
in some cases might be driven by novel promoters (Faulkner et al.
2009; Djebali et al. 2012; The ENCODE Project Consortium 2012).
We used chromatin states defined by combinations of histone
modifications to identify previously unannotated promoters that
are hypomethylated in GBM. We confirmed promoter activity in
GBM cell lines for gene body promoters in TNXB, PAX7, and
SIGLEC11. The SIGLEC11 gene body promoter is located within
an ERV-derived repeat, and we found that a gene body transcript
can be up-regulated in a subset of GBMs with hypomethylation at
this locus. This highlights the potential functional importance of
epigenetic alterations at transposons in GBM. Our approach used
chromatin state information from ENCODE cell lines and likely
includes only a subset of all possible promoter regions, but suggests
that using complementary epigenomic data in addition to con-
ventional annotations will provide a more complete understanding
of epigenetic (and genetic) alterations.
We noted many loci where GBM hypomethylation colo-
calizes with ENCODE ChromHMM enhancers. In chronic lym-
phocytic leukemia (CLL), a subset of gene body hypomethylation
colocalized with enhancers, correlating in some cases with gene
expression changes (Kulis et al. 2012). In colon cancer, 662 focally
hypomethylated elements were enriched for TAF1 and other
transcription factor binding in ENCODE cell lines, suggesting
that these hypomethylated loci function as promoters or en-
hancers (Berman et al. 2011). In future studies, comparing the
recurrent DNA hypomethylated loci to GBM enhancer profiles
assayed by ChIP-seq with H3K27ac and H3K4me1 would be of
great interest, especially since enhancers show strong cell type
specificity.
We generated sample-matchedH3K4me3ChIP-seq profiles to
explore the relationship between promoter-associated histone
modifications and DNA hypomethylation. GBM promoters were
determined byH3K4me3 peak calling, although some peaksmight
be associated with low transcriptional activity. We hypothesized
that the dual presence of DNA hypomethylation and H3K4me3
wouldmore strongly enrich for functional hypomethylation events.
Most hypomethylated DMRs did not colocalize with H3K4me3
assayed in the same tumor. However, 200 hypomethylated DMRs
did colocalize with H3K4me3 in the same tumor, and we found
increased expression of genes containing dual DNA hypo/K4me3
loci in their gene bodies. TheGLI3 oncogene contained a gene body
promoter with recurrent DNA hypomethylation and H3K4me3,
and we found that the Delta GLI3 transcript expressed from this
promoter was up-regulated in two GBMswith these dual epigenetic
marks.
In contrast to our findings, a breast cancer methylome study
found that some hypomethylation was allelic with the non-
hypomethylated allele occupied by repressive chromatin marks
H3K9me3 or H3K27me3, associated with gene silencing (Hon
et al. 2012).We did not examineH3K9me3 or H3K27me3, but our
data show that a limited number of hypomethylated loci are as-
sociated with gene activation rather than repression. The genetic
and epigenetic contexts are likely important for determining the
effect of individual hypomethylation events, which might have
diverse consequences from one locus to another, or from one
tumor to another.
Finally, we examined in detail the molecular consequences of
hypomethylation at gene body promoters within TP73 and TERT,
two genes with functions important to cancer. Our study is the first
to detect deltaNp73 oncoprotein expression in GBM. DeltaNp73
competes for p53 and full-length p73 binding sites and inhibits
activation of apoptosis in cancer cells (Ishimoto et al. 2002).
DeltaNp73 retains DNA binding but not transactivation functions,
and thus acts as a dominant-negative inhibitor of both p53 and p73
by direct competition for binding to genomic targets. We also un-
covered GBM-specific expression of a novel TERT alternate tran-
script from a hypomethylated gene body promoter. TheDelta TERT
transcript initiates within intron 2 and encodes a putative delta
TERT protein lacking most of the reverse transcriptase domain
but gaining a unique N terminus, similar to the general pattern in
deltaNp73.Wewere unable to determine if the delta TERT protein
is expressed in GBM due to the lack of a specific anti-C-terminal
antibody. Alternatively spliced TERT variants lacking reverse
transcriptase activity enhanced cell proliferation and stimulated
WNT signaling (Hrdlickova et al. 2012). Full-length TERT physi-
cally interacts with the SWI/SNF-related chromatin remodeling
protein SMARCA4, and occupies and activates WNT-dependent
genes, indicating a role in transcriptional activation (Park et al.
2009). It remains to be determined whether delta TERT is simi-
larly multifunctional and has telomere-independent oncogenic
properties.
Our global and gene-specific analyses implicate a subset of
gene body promoter hypomethylation in up-regulating alternate
transcripts with potential oncogenic consequences in GBM. Some
of the expressed RNAsmight be transcriptional noise or noncoding
RNAs. However, the gene body transcripts initiating within TP73,
TERT, and GLI3 all encode known or putative alternate proteins.
Methylation-regulated gene body promoters confer protein di-
versity among normal tissues, and our data suggest that gene body
hypomethylation might contribute to the up-regulation of onco-
genic protein isoforms in GBM as well.
Methods
MeDIP-seq and MRE-seq
DNAwas isolated from frozen tissue and tumor specimens by 55°C
overnight digestion in SDS/Tris/EDTA/Proteinase K lysis buffer
followed by two phenol/chloroform/isoamyl alcohol extractions
then two chloroform extractions, precipitation with sodium ace-
tate and ethanol, one 70% ethanol wash, and resuspension in TE
buffer. MeDIP- and MRE-seq were performed as previously de-
scribed (Maunakea et al. 2010) with the following modifications.
For GBM 5, the MRE-seq library was constructed using five re-
striction enzymedigests (HpaII, AciI, Hin6I, Bsh1236I, HpyCH4IV)
instead of the three (HpaII, AciI, Hin6I) used for all other samples.
GBM 5 MRE-seq reads were informatically filtered to include only
those from the three-enzyme protocol to make the GBM 5 data
comparable to other samples.
Processing of MeDIP-seq and MRE-seq data
MeDIP-seq and MRE-seq reads from GBM (this study) and two
normal brains (Maunakea et al. 2010) (NCBI Sequence Read Archive
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accessionnumber SRP002318)were alignedwithBowtie (Langmead
2010) to hg19. Only uniquely mapping reads were used for down-
stream analyses. ForMRE-seq, an additional constraint is that the 59
end of a read must map to the CpG site within a methyl-sensitive
restriction enzyme site. For MRE-seq, duplicate reads with identical
start positions and sequences are retained, but duplicates were fil-
tered fromMeDIP-seq data to retain only one read. MRE reads were
normalized to account for differences in enzyme efficiency and
scoring consisted of tabulating reads with CpGs at each fragment
end (Maunakea et al. 2010). For display of GBM MeDIP-seq and
MRE-seq on the browser, uniquely mapping reads were normalized
by aCGH copy number. To normalize for differences in sequencing
depth, MeDIP-seq was normalized to 50 M reads and MRE-seq to
20 M reads. The MeDIP-seq tracks show the density of coverage,
based on extension of each read to the average fragment size. For
MRE-seq, an MRE score was defined for each MRE CpG site as the
normalized number of MRE reads that map to the site, regardless of
the orientation of the read.
M&M analysis of MeDIP- and MRE-seq to identify DMRs
The coverage of sequencing data (MeDIP-seq and MRE-seq) and
genomic CpG information were calculated in a 500-bp window
across the human genome (hg19 assembly), excluding autosomes.
Agilent array CGH copy number estimates by segment (see below)
were used to scale theMeDIP-seq andMRE-seq counts.We used the
seqCBS algorithm (Shen and Zhang 2012) on the MeDIP-seq se-
quencing data to further refine the segments identified by CBS on
the Agilent data, since there is ambiguity in the genomic regions
between Agilent markers. SeqCBS segments sequencing data in
a manner analogous to CBS based on changes in the ratio of test
counts to test plus reference counts.We usedMeDIP-seq reads, and
not MRE-seq, to refine the genomic positions of copy number
segments because its sequencing reads are more evenly distributed
across the genome. MRE-seq reads are sparser because they derive
from unmethylated CpGs located within MRE recognition sites
that generate fragments of a specific size range when digested. To
refine the segments for each GBM, we compiled the genomic re-
gions that were between the CGH array probes at the ends of ad-
jacent copy number segments (‘‘gap regions’’) and ran seqCBS,
using MeDIP-seq reads from GBM and normal brain 1 as test and
reference, respectively. SeqCBS analyzes the ratio of test/test +
reference to find changepoints. For each gap region, if seqCBS
could call a single changepoint, we used this genomic position as
the new copy number breakpoint for adjacent segments. If seqCBS
could not identify a single changepoint, we used the midpoint
between the CGH probes as the new changepoint. In this way, we
closed all of the gap regions. Sequencing depth normalization on
the MeDIP-seq and MRE-seq data was performed after CNV nor-
malization. The R package methylMnM (http://epigenome.wustl.
edu/MnM/; Zhang et al. 2013) was used to identify DMRs by paired
comparison between eachnormal brain sample and eachGBM.Only
windows on autosomes were considered. Windows with significant
Q-values comparedwithbothnormal brainswere identified asDMRs,
at eitherQ < 105 orQ < 1013. These thresholds were determined by
comparingM&Manalysis ofMeDIP- andMRE-seq onH1 embryonic
stem cells to shotgun bisulfite sequencing data from the same cells.
Array-CGH and copy number segmentation analysis
Array CGH was performed on the Agilent 244K platform for each
GBM using 500 ng of DNA and followingmanufacturer’s protocol.
Pooled normalDNA, different from the normal brainDNAused for
methylation analysis, was used for the reference. All samples
passed Agilent’s quality control metrics. We utilized the circular
binary segmentation (CBS) method (Venkatraman and Olshen
2007) to estimate copy number. This method splits the genome,
one chromosome at a time, into regions of equal number based on
changes in the distribution of log tumor to reference values. The
estimated copy number in each segment is based on the average of
the log ratios in the segment. Before segmentation, the copy
number data were GC-normalized. To confirm the accuracy of our
copy number segmentation, we downloaded TCGA copy number
array data (Agilent and Affymetrix) for GBMs 2 and 3, and com-
pared the segmentation values with our own. Across all chromo-
somes, the segmentations were highly similar (data not shown).
Illumina Infinium HumanMethylation27 array
A total of 500ng of genomicDNAper samplewas used for Infinium
methylation array analysis. Bisulfite conversion was performed
with the EZ DNA methylation kit (Zymo Research) and each
sample was eluted in 12 mL water. Amplification and hybridization
to the HumanMethylation27 BeadChipwere carried out according
tomanufacturer’s instructions at theUCSFGenomics Core Facility.
Beta values, representing quantitative measurements of DNA
methylation at individual CpGs, were generated with Illumina
GenomeStudio software. Beta values were normalized to back-
ground and filtered to remove those with low signal intensity. The
filtered data were used for all subsequent analysis.
Expression microarrays
High-quality total RNA was prepared by TRIzol (Invitrogen) puri-
fication and confirmed by RIN value determined from Agilent
Bioanalyzer analysis. Expression analysis was performed on the
Affymetrix GeneChip Human Gene 1.0 ST platform at the UCSF
Gladstone Genomics Core. Data normalization was performed by
the Robust Multi-array Average (RMA) method.
Bisulfite sequencing
Total genomic DNA was bisulfite converted as per the protocol of
Grunau et al. (2001), with modified conversion conditions: 95°C
for 1 min, 50°C for 59 min for a total of 16 cycles. Locus-specific
PCR primers were designed with MethPrimer (Supplemental Table
S5; Li and Dahiya 2002). PCR products were TOPO TA cloned into
pCR2.1/TOPO (Invitrogen). At least 10 individual colonies were
sequenced per sample. DNA methylation patterns and levels were
analyzed suing BISMA (Rohde et al. 2010).
Processing of Roadmap Epigenomics histone modification data
H3K4me3ChIP-seq data of relevant cell types were produced as part
of the Roadmap Epigenomics project (Bernstein et al. 2010) and
deposited to GEO (GSE16368). Mapped read density was generated
from aligned sequencing reads using customized Perl scripts. Read
density overlapping DMRs and their 5-kb upstream/downstream
regions were extracted at 50-bp resolution as RPKM values, with
histone input data subtracted.
ENCODE HMM chromatin state annotation
ChromHMM annotation of nine ENCODE cell lines (Ernst et al.
2011)was obtained from theUCSCGenomeBrowser (Rosenbloom
et al. 2012). The nine cell lines are the following:H1ESC,GM12878,
K562, HepG2, HUVEC, HMEC, HSMM, NHEK, and NHLF. For each
DMR, we examined overlapping annotation of ‘‘promoter,’’ ‘‘en-
hancer,’’ and ‘‘insulator’’ states in these ChromHMM maps. We
determined that 3.3% of background genomic windows were
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potential promoters, 17.3% were potential enhancers, and 1.4%
potential insulators.
Genomic features
RepeatMasker annotations, CGIs, UCSCGene, and refGene coding
loci features were all downloaded from the UCSCGenome Browser
(Kent et al. 2002; Meyer et al. 2013).
qRT-PCR
Total RNA was isolated by TRIzol. cDNA synthesis was performed
with amix of randomhexamer and oligo dTusingMoloneyMurine
Leukemia Virus Reverse Transcriptase (Invitrogen). Real-time RT-
PCR was performed with the Opticon2 Continuous Fluorescence
Detector (MJ Research) and relative expression levels calculated
using the deltaCt method with GAPDH as a housekeeping control.
Melting curves were inspected to confirm PCR specificity. Primers
are listed in Supplemental Table S5.
Western blotting
GBM primary tumor, GBM cell line, and normal brain lysates were
electrophoresed on 4%–20% polyacrylamide with SDS, transferred
to PVDF by wet transfer, blocked, and then probed with mouse
1:100 anti-DeltaNp73 (Calbiochem #38C674) and rabbit 1:1000
anti-GAPDH (Cell Signaling # 14C10) antibodies. After incuba-
tion with labeled secondary antibodies, a signal was detected by
chemiluminescence.
Luciferase promoter assay
Target lociwere PCR-amplified fromnormalhumanbrainDNAwith
primers containing added restriction sites (Supplemental Table 5).
PCRproductswere purified, restrictiondigested, and cloned into the
pGL3-Basic vector (Promega). One microgram of each vector was
cotransfected with 10 ng (1:100) of pRL-TK (Promega) expressing
Renilla luciferase by using FuGENE 6 (Roche). After 48 h, firefly
luciferase activity was measured by using the Dual-Luciferase re-
porter assay system (Promega) and normalized against Renilla lu-
ciferase activity. The pGL3 basic vector was used as a basal level of
luciferase activity, and the pGL3 ‘‘promoter’’ vector containing the
SV40 promoter was used as a positive control.
Chromatin immunoprecipitation-sequencing (ChIP-seq)
Chromatin isolated from GBMs 1, 2, and 5 frozen tissue was
digested to mononucleosomes with micrococcal nuclease. His-
tones marked with H3K4me3 were immunoprecipitated with
a monoclonal antibody (Cell Signaling, Catalog # 9751) using
Sepharose beads coated in Protein A/G, and the DNA purified. An
IgG negative control was performed in each experiment and
quantitative PCR verified enrichment. Illumina library construc-
tion was performed as per manufacturer’s instructions. A total of
75-bp single-end or paired-end sequencing was performed on the
Illumina HiSeq. As a control, input DNA from each chromatin
preparation was also sequenced. The resulting sequences were
quality filtered and mapped back to the human genome using the
Burrows-Wheeler Aligner (Li and Durbin 2010). The sequencing
libraries were aligned as single-end samples to ensure equal map-
ping bias across the samples. ChIP enrichment was further verified
usingCHANCE (Diaz et al. 2012). Peak callingwas performed using
MACS at a 1% false discovery rate and a P-value < 13 1010 (Zhang
et al. 2008).
59-RACE
Total RNA was isolated by TRIzol (Invitrogen) and used to amplify
the 59 end of the putative Delta TERTmRNA using the Gene Racer
kit (Invitrogen) following the manufacturer’s protocol. The TERT
gene-specific primers are listed in Supplemental Table 5. The am-
plification products were gel-purified, cloned into pCR4-TOPO
(Invitrogen), and inserts were sequenced.
Data access
MeDIP-seq,MRE-seq, andChIP-seq data have been submitted to the
European Genome-phenome Archive (EGA; http://www.ebi.ac.uk/
ega/) under accession number EGAS00001000685. Affymetrix
GeneChip Human Gene 1.0 ST and Agilent 244K array-CGH data
have been submitted to the NCBI Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession num-
bers GSE49412 and GSE49808.
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